Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
NCT07149038, Not applicable, Active not recruiting, Neurogrin Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT07149038 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 24 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Neurogrin Inc. | ClinicalTrials.gov |
| Conditions | Vascular Dementia, Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Cerogrin, Sham Device | ClinicalTrials.gov |
| First posted | 2025-08-29 | ClinicalTrials.gov |
| Last updated | 2026-09-18 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | The CDR-SB is a scale that evaluates a patient's cognitive function and ability to live independently. The scores range from 0 to 18, with higher scores indicating more severe cognitive impairment. | ClinicalTrials.gov |
| Primary | Change from Baseline in Korean Montreal Cognitive Assessment (K-MoCA) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | he K-MoCA is a cognitive screening tool used to detect mild cognitive impairment. Scores range from 0 to 30, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Change from Baseline in Korean Mini-Mental State Examination-2 (K-MMSE-II) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | The K-MMSE-II is a cognitive screening test used to assess a person's cognitive function, with scores ranging from 0 to 30. | ClinicalTrials.gov |
| Primary | Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | The ADAS-cog 13 is a scale used to assess the severity of cognitive symptoms in Alzheimer's disease. Higher scores indicate greater cognitive impairment. | ClinicalTrials.gov |
| Primary | Change from Baseline in Controlled Oral Word Association Test (COWAT) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | This test measures a person's verbal fluency and executive function. | ClinicalTrials.gov |
| Primary | Change from Baseline in Stroop Test Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | The Stroop test measures a person's cognitive flexibility and executive function. | ClinicalTrials.gov |
| Primary | Change from Baseline in Trail Making Test (TMT) Score | Baseline to Week 4 (End of Intervention Period) and/or Week 8 (End of Follow-up) | The TMT is a neuro-psychological test of visual attention and task switching. | ClinicalTrials.gov |
| Secondary | Change from Baseline in DTI-ALPS Score on Magnetic Resonance Imaging (MRI) | Baseline to Week 4 (End of Intervention Period) | This score evaluates the brain's perivascular space, which is related to cerebral small vessel disease. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Brain Function using Functional Magnetic Resonance Imaging (fMRI) | Baseline to Week 4 (End of Intervention Period) | This method measures brain activity by detecting changes in blood flow. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Electroencephalogram (EEG) Brain Wave Analysis | Baseline to Week 4 (End of Intervention Period) | Descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum) for changes in EEG power and relative EEG power by brainwave frequency band will be presented for each group. Statistical significance of the differences between groups will be tested using ANCOVA, with the indication (vascular dementia/vascular mild cognitive impairment) and baseline relative EEG power as covariates. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)